Compare Amgen, Inc. (AMGN) vs Booz Allen Hamilton Holding Corporation (BAH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Booz Allen Hamilton Holding Corporation — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Booz Allen Hamilton Holding Corporation trades at $63.6 (market cap $7.53B). The key difference: Amgen, Inc. is far larger — about 26× Booz Allen Hamilton Holding Corporation's market cap, and Booz Allen Hamilton Holding Corporation pays the higher dividend (3.76%). Which is the better fit depends on your goals.
| AMGN | BAH | |
|---|---|---|
Market Cap | $196.12B | $7.53B |
Sector | Health | Industrials |
52-Week High | $388.16 | $115.95 |
52-Week Low | $271.18 | $59.71 |
Enterprise Value | $241.41B | $10.92B |
Dividend Yield | 2.77% | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Booz Allen Hamilton (BAH) trades at $62.76, down 0.63% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 9.1 and robust profitability, including an 80.17% ROE. Recent earnings have mostly beaten estimates, and the company announced a partnership with OpenAI to advance AI in national security. Cash flow from operations improved to $1.01B in 2025, though net cash flow turned negative in 2026 projections.
BAH presents a compelling value opportunity with solid earnings growth and a consensus price target of $80.80, implying significant upside. Risks include persistent civil segment weakness noted in guidance and rising debt-to-asset ratios. Investor sentiment is mixed, with nearly half of analysts rating it a buy, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →
